Drug Trial Radar · NCT07225270
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
544
Planned (sponsor's estimate)
Start
Apr 3, 2026
Primary completion
Oct 2028
Study completion May 2030
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer. Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.
Conditions
- Ovarian Cancer
- Platinum-sensitive Ovarian Cancer
- PSOC
Interventions
Rina-SDrug
Intravenous (IV) infusion
BevacizumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years
Locations
69 sites in 16 countries. Site status is shown where the registry gives one.
University Of California Davis Medical Center
Sacramento, California · Recruiting
Hartford Hospital
Hartford, Connecticut · Recruiting
Mt. Sinai Comprehensive Cancer Center
Miami, Florida · Recruiting
Florida Cancer Specialists & Research Institute - New Port Richey
New Port Richey, Florida · Recruiting
Sarasota Memorial Health Care System
Sarasota, Florida · Recruiting
Maine Medical Center Cancer Institute Breast Care Center
Scarborough, Maine · Recruiting
Greater Baltimore Medical Center
Towson, Maryland · Recruiting
Missouri Cancer Associates
Columbia, Missouri · Recruiting
Methodist Estabrook Cancer Center
Omaha, Nebraska · Recruiting
Novant Health Presbyterian Medical Center
Charlotte, North Carolina · Recruiting
Miami Valley Hospital South
Centerville, Ohio · Recruiting
Zangmeister Cancer Center
Columbus, Ohio · Recruiting
Penn State Health Milton South Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Alliance Cancer Specialists - Abington Hematology Oncology Associates - Horsham
Horsham, Pennsylvania · Recruiting
Texas Oncology - Northeast Texas
San Antonio, Texas · Recruiting
Virginia Cancer Specialists - Fairfax
Fairfax, Virginia · Recruiting
Prince of Wales Hospital
Randwick, Australia · Recruiting
Medizinische Universitaet Innsbruck
Innsbruck, Austria · Recruiting
Les Cliniques du Sud Luxembourg, Clinique Saint-Joseph
Arlon, Belgium · Recruiting
AZ Maria Middelares
Ghent, Belgium · Recruiting
UZ Leuven - Gasthuisberg Campus
Leuven, Belgium · Recruiting
AZ Delta - Uw Ziekenhuis
Roeselare, Belgium · Recruiting
AZ Nikolaas
Sint-Niklaas, Belgium · Recruiting
Aalborg University Hospital
Aalborg, Denmark · Recruiting
Roskilde Sygehus
Roskilde, Denmark · Recruiting
Kuopion Yliopistollinen Sairaala
Kuopio, Finland · Recruiting
Oulu University Hospital
Oulu, Finland · Recruiting
Tampereen yliopistollinen sairaala - Tampere
Tampere, Finland · Recruiting
Tyks Majakkasairaala
Turku, Finland · Recruiting
Centre Hospitalier de Mont-de-Marsan
Mont-de-Marsan, France · Recruiting
Hôpital Privé du Confluent
Nantes, France · Recruiting
Centre Antoine-Lacassagne - Site Est
Nice, France · Recruiting
Groupe Hospitalier Paris Saint-Joseph
Paris, France · Recruiting
Centre Hospitalier Universitaire de Poitiers
Poitiers, France · Recruiting
Hôpital René Huguenin
Saint-Cloud, France · Recruiting
Klinikum Gütersloh
Gütersloh, Germany · Recruiting
SLK-Kliniken Heilbronn
Heilbronn, Germany · Recruiting
Ospedale Humanitas San Pio X
Milan, Italy · Recruiting
The Jikei University Kashiwa Hospital
Kashiwa, Japan · Recruiting
St Marianna University School of Medicine
Kawasaki, Japan · Recruiting
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.